Use of Precision Imaging in the Evaluation of Pancreas Cancer

2019 ◽  
pp. 209-236 ◽  
Author(s):  
Ronald L. Korn ◽  
Syed Rahmanuddin ◽  
Erkut Borazanci
Keyword(s):  
Pancreas Cancer

scholarly journals Phase II study of selumetinib, an orally active inhibitor of MEK1 and MEK2 kinases, in KRASG12R-mutant pancreatic ductal adenocarcinoma

2021 ◽  
Author(s):  
Cara Kenney ◽  
Tricia Kunst ◽  
Santhana Webb ◽  
Devisser Christina ◽  
Christy Arrowood ◽  
...  
Keyword(s):  
Cancer Patients ◽  
Phase Ii ◽  
Pancreas Cancer ◽  
Phase Ii Study ◽  
Mapk Pathway ◽  
Single Agent ◽  
Objective Response ◽  
Ductal Adenocarcinoma ◽  
Active Inhibitor ◽  
Orally Active

SummaryBackground Preclinical evidence has suggested that a subset of pancreatic cancers with the G12R mutational isoform of the KRAS oncogene is more sensitive to MAPK pathway blockade than pancreatic tumors with other KRAS isoforms. We conducted a biomarker-driven trial of selumetinib (KOSELUGO™; ARRY-142886), an orally active, allosteric mitogen-activated protein kinase 1 and 2 (MEK1/2) inhibitor, in pancreas cancer patients with somatic KRASG12R mutations. Methods In this two-stage, phase II study (NCT03040986) patients with advanced pancreas cancer harboring somatic KRASG12R variants who had received at least one standard-of-care systemic therapy regimen received 75 mg selumetinib orally twice a day until disease progression or unacceptable toxicity occurred. The primary outcome of the study was best objective response (BOR). Results From August 2017 to February 2018 a total of 8 patients with confirmed somatic KRASG12R mutations and a median age of 61.5 years were treated with selumetinib. Seven out of eight (87.5%) had received two or more lines of prior systemic chemotherapy. After a median follow-up period of 8.5 months (range 2 to 20), three patients had stable disease for more than 6 months while receiving selumetinib. No patients achieved an objective partial response. Median progression-free survival (PFS) was 3.0 months (95% CI, 0.8–8.2) and median overall survival (OS) 9 months (95% CI, 2.5–20.9). Conclusion This study in heavily pre-treated pancreatic adenocarcinoma patients suggests alternative strategies beyond single agent MEK inhibition are required for this unique, molecular subset of pancreatic cancer patients. The trial was registered on February 2nd, 2017 under identifier NCT03040986 with ClinicalTrials.gov.

T2044 Family History of Pancreas, Breast, Colon, Bladder, and Prostate Cancer in Patients with Pancreas Cancer Supports a Syndromic Predisposition

2008 ◽  
Vol 134 (4) ◽  
pp. A-607
Author(s):  
Aimee L. Lucas ◽  
Aliye Z. Bill ◽  
Caroline Hwang ◽  
Elizabeth Verna ◽  
Nicole Goetz ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Family History ◽  
Pancreas Cancer ◽  
History Of

P27 Antiangiogenic activity of combining gefitinib and rapamycin in a panel of pancreas cancer cell lines

2007 ◽  
Vol 5 (8) ◽  
pp. 31
Author(s):  
L. Pocelli ◽  
A. Azzariti ◽  
G.M. Simone ◽  
G. Gatti ◽  
A. Nicolin ◽  
...  
Keyword(s):  
Cell Lines ◽  
Cancer Cell ◽  
Pancreas Cancer ◽  
Cancer Cell Lines ◽  
Antiangiogenic Activity

scholarly journals The Wnt pathway is active in a small subset of pancreas cancer cell lines

2006 ◽  
Vol 1762 (1) ◽  
pp. 73-79 ◽  
Author(s):  
Judit Pujal ◽  
Gabriel Capellá ◽  
Francisco X. Real
Keyword(s):  
Cell Lines ◽  
Cancer Cell ◽  
Wnt Pathway ◽  
Pancreas Cancer ◽  
Cancer Cell Lines ◽  
Small Subset
Sign in / Sign up

Export Citation Format

Share Document